Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Police break up illegal chicken slaughter in Germany- McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
